Frontiers in Psychiatry (Nov 2021)

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients

  • Suguru Nakajima,
  • Suguru Nakajima,
  • Yuko Higuchi,
  • Yuko Higuchi,
  • Takahiro Tateno,
  • Takahiro Tateno,
  • Daiki Sasabayashi,
  • Daiki Sasabayashi,
  • Yuko Mizukami,
  • Shimako Nishiyama,
  • Shimako Nishiyama,
  • Tsutomu Takahashi,
  • Tsutomu Takahashi,
  • Michio Suzuki,
  • Michio Suzuki

DOI
https://doi.org/10.3389/fpsyt.2021.777378
Journal volume & issue
Vol. 12

Abstract

Read online

Objective: Remission in schizophrenia patients is associated with neurocognitive, social, and role functioning during both the early and chronic stages of schizophrenia. It is well-established that the amplitudes of duration mismatch negativity (dMMN) and frequency MMN (fMMN) are reduced in schizophrenia patients. However, the potential link between MMN and remission has not been established. In this study, we investigated the relationship between MMNs and remission in first-episode schizophrenia (FES) and their association with neurocognitive and social functioning.Method: dMMN and fMMN were measured in 30 patients with FES and 22 healthy controls at baseline and after a mean of 3 years. Clinical symptoms and cognitive and social functioning in the patients were assessed at the time of MMN measurements by using the Positive and Negative Syndrome Scale (PANSS), modified Global Assessment of Functioning (mGAF), Schizophrenia Cognition Rating Scale (SCoRS), and the Brief Assessment of Cognition in Schizophrenia (BACS). Remission of the patients was defined using the criteria by the Remission in Schizophrenia Working Group; of the 30 patients with FES, 14 achieved remission and 16 did not.Results: Baseline dMMN amplitude was reduced in FES compared to healthy controls. Further, baseline dMMN in the non-remitters had decreased amplitude and prolonged latency compared to the remitters. MMN did not change during follow-up period regardless of parameters, diagnosis, or remission status. Baseline dMMN amplitude in FES was correlated with future SCoRS and PANSS total scores. Logistic regression analysis revealed that dMMN amplitude at baseline was a significant predictor of remission.Conclusions: Our findings suggest that dMMN amplitude may be a useful biomarker for predicting symptomatic remission and improvement of cognitive and social functions in FES.

Keywords